Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
November 26 2019 - 8:00AM
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a
biopharmaceutical company utilizing sophisticated computational
methods to design de novo protein therapeutics, today
announced that Jonathan Drachman, M.D., Chief Executive Officer,
will present at the Piper Jaffray 31st Annual Healthcare Conference
on Thursday, December 5, 2019 at 2:50 p.m. EST in New York.
A live webcast of the presentation will be available from the
investors section of the Neoleukin website at
http://investor.neoleukin.com/events. An archived replay of the
presentation will also be available on the company website for at
least 30 days following the event.
About Neoleukin Therapeutics, Inc.Neoleukin is
a biopharmaceutical company creating next generation
immunotherapies for cancer, inflammation, and autoimmunity
using de novo protein design technology. Neoleukin
uses sophisticated computational methods to design proteins that
demonstrate specific pharmaceutical properties that provide
potentially superior therapeutic benefit over native
proteins. Neoleukin’s lead product candidate, NL-201, is a
combined IL-2 and IL-15 agonist designed to eliminate alpha
receptor binding. For more information, please visit the Neoleukin
website: www.neoleukin.com.
Cautionary Note on Forward-Looking
Statements Certain of the statements made in this press
release are forward looking, including those relating to evaluation
of our pipeline and strategic options, potential timing of
preclinical data, the sufficiency of our cash resources and other
statements containing the words “anticipate,” “believe,” “expect,”
“may,” “plan,” “project,” “potential,” “will,” “would,” “could,”
“continue,” and similar expressions. These statements are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, risks and uncertainties related to: clinical drug
development is a lengthy and expensive process with an uncertain
outcome; our ability to identify or acquire additional clinical
candidates, our ability to obtain and maintain regulatory
approval for any future product candidates and the potential
safety, efficacy or clinical utility of or any future product
candidates. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. More information about the risks and uncertainties
faced by Neoleukin is contained in the company’s Quarterly Report
on Form 10-Q filed with the Securities and Exchange
Commission. Neoleukin disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian
Korb646-378-2923bkorb@troutgroup.com
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Apr 2023 to Apr 2024